Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Defraene

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Acta Oncologica (Stockholm, Sweden)|October 13, 2016
Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico studyAngela Botticella, Gilles Defraene, Kristiaan Nackaerts, et al.
International Journal of Radiation Oncology, Biology, Physics|June 14, 2011
The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancerGilles Defraene, Laura Van den Bergh, Abrahim Al-Mamgani, et al.
Medical Physics|June 1, 2014
Dosimetric adaptive IMRT driven by fiducial pointsWouter Crijns, Hans Van Herck, Gilles Defraene, et al.
Respiration; International Review of Thoracic Diseases|November 12, 2025
Drug-Induced Interstitial Lung Disease in Lung Cancer PatientsGilles Vanhandsaeme, Karolien Viskens, Valerie Van Ballaer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 27, 2022
Automated clinical decision support system with deep learning dose prediction and NTCP models to evaluate treatment complications in patients with esophageal cancerCamille Draguet, Ana M Barragán-Montero, Macarena Chocan Vera, et al.
BMC Cancer|May 10, 2020
Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastasesPatrick Berkovic, Akos Gulyban, Gilles Defraene, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 25, 2019
Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancerGilles Defraene, Frank J W M Dankers, Gareth Price, et al.
Acta Oncologica (Stockholm, Sweden)|August 21, 2013
Quantification of radiation-induced lung damage with CT scans: the possible benefit for radiogenomicsDirk De Ruysscher, Hoda Sharifi, Gilles Defraene, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 17, 2016
Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statementDirk De Ruysscher, Gilles Defraene, Bram L T Ramaekers, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 7, 2020
Proposal for the delineation of neoadjuvant target volumes in oesophageal cancerMelissa Thomas, Hanna R Mortensen, Lone Hoffmann, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Acta Oncologica (Stockholm, Sweden)|October 13, 2016
Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico studyAngela Botticella, Gilles Defraene, Kristiaan Nackaerts, et al.
International Journal of Radiation Oncology, Biology, Physics|June 14, 2011
The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancerGilles Defraene, Laura Van den Bergh, Abrahim Al-Mamgani, et al.
Medical Physics|June 1, 2014
Dosimetric adaptive IMRT driven by fiducial pointsWouter Crijns, Hans Van Herck, Gilles Defraene, et al.
Respiration; International Review of Thoracic Diseases|November 12, 2025
Drug-Induced Interstitial Lung Disease in Lung Cancer PatientsGilles Vanhandsaeme, Karolien Viskens, Valerie Van Ballaer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 27, 2022
Automated clinical decision support system with deep learning dose prediction and NTCP models to evaluate treatment complications in patients with esophageal cancerCamille Draguet, Ana M Barragán-Montero, Macarena Chocan Vera, et al.
BMC Cancer|May 10, 2020
Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastasesPatrick Berkovic, Akos Gulyban, Gilles Defraene, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 25, 2019
Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancerGilles Defraene, Frank J W M Dankers, Gareth Price, et al.
Acta Oncologica (Stockholm, Sweden)|August 21, 2013
Quantification of radiation-induced lung damage with CT scans: the possible benefit for radiogenomicsDirk De Ruysscher, Hoda Sharifi, Gilles Defraene, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 17, 2016
Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statementDirk De Ruysscher, Gilles Defraene, Bram L T Ramaekers, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 7, 2020
Proposal for the delineation of neoadjuvant target volumes in oesophageal cancerMelissa Thomas, Hanna R Mortensen, Lone Hoffmann, et al.
Pageof 5